267 related articles for article (PubMed ID: 20378548)
1. Toward classification of BRCA1 missense variants using a biophysical approach.
Rowling PJ; Cook R; Itzhaki LS
J Biol Chem; 2010 Jun; 285(26):20080-7. PubMed ID: 20378548
[TBL] [Abstract][Full Text] [Related]
2. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
Drikos I; Nounesis G; Vorgias CE
Proteins; 2009 Nov; 77(2):464-76. PubMed ID: 19452558
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1.
Ekblad CM; Wilkinson HR; Schymkowitz JW; Rousseau F; Freund SM; Itzhaki LS
J Mol Biol; 2002 Jul; 320(3):431-42. PubMed ID: 12096901
[TBL] [Abstract][Full Text] [Related]
4. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Tischkowitz M; Hamel N; Carvalho MA; Birrane G; Soni A; van Beers EH; Joosse SA; Wong N; Novak D; Quenneville LA; Grist SA; ; Nederlof PM; Goldgar DE; Tavtigian SV; Monteiro AN; Ladias JA; Foulkes WD
Eur J Hum Genet; 2008 Jul; 16(7):820-32. PubMed ID: 18285836
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Lee MS; Green R; Marsillac SM; Coquelle N; Williams RS; Yeung T; Foo D; Hau DD; Hui B; Monteiro AN; Glover JN
Cancer Res; 2010 Jun; 70(12):4880-90. PubMed ID: 20516115
[TBL] [Abstract][Full Text] [Related]
6. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
[No Abstract] [Full Text] [Related]
7. Cancer-related mutations in BRCA1-BRCT cause long-range structural changes in protein-protein binding sites: a molecular dynamics study.
Gough CA; Gojobori T; Imanishi T
Proteins; 2007 Jan; 66(1):69-86. PubMed ID: 17063491
[TBL] [Abstract][Full Text] [Related]
8. Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis.
Ekblad CM; Friedler A; Veprintsev D; Weinberg RL; Itzhaki LS
Protein Sci; 2004 Mar; 13(3):617-25. PubMed ID: 14978302
[TBL] [Abstract][Full Text] [Related]
9. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
Mirkovic N; Marti-Renom MA; Weber BL; Sali A; Monteiro AN
Cancer Res; 2004 Jun; 64(11):3790-7. PubMed ID: 15172985
[TBL] [Abstract][Full Text] [Related]
10. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
[TBL] [Abstract][Full Text] [Related]
11. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
Fernandes VC; Golubeva VA; Di Pietro G; Shields C; Amankwah K; Nepomuceno TC; de Gregoriis G; Abreu RBV; Harro C; Gomes TT; Silva RF; Suarez-Kurtz G; Couch FJ; Iversen ES; Monteiro ANA; Carvalho MA
J Biol Chem; 2019 Apr; 294(15):5980-5992. PubMed ID: 30765603
[TBL] [Abstract][Full Text] [Related]
12. Protein stability versus function: effects of destabilizing missense mutations on BRCA1 DNA repair activity.
Gaboriau DC; Rowling PJ; Morrison CG; Itzhaki LS
Biochem J; 2015 Mar; 466(3):613-24. PubMed ID: 25748678
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
14. Functional and structural analysis of C-terminal BRCA1 missense variants.
Quiles F; Fernández-Rodríguez J; Mosca R; Feliubadaló L; Tornero E; Brunet J; Blanco I; Capellá G; Pujana MÀ; Aloy P; Monteiro A; Lázaro C
PLoS One; 2013; 8(4):e61302. PubMed ID: 23613828
[TBL] [Abstract][Full Text] [Related]
15. Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
De Nicolo A; Parisini E; Zhong Q; Dalla Palma M; Stoeckert KA; Domchek SM; Nathanson KL; Caligo MA; Vidal M; Cusick ME; Garber JE
Cancer Res; 2009 Sep; 69(17):7030-7. PubMed ID: 19706752
[TBL] [Abstract][Full Text] [Related]
16. Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.
Coquelle N; Green R; Glover JN
Biochemistry; 2011 May; 50(21):4579-89. PubMed ID: 21473589
[TBL] [Abstract][Full Text] [Related]
17. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.
Williams RS; Glover JN
J Biol Chem; 2003 Jan; 278(4):2630-5. PubMed ID: 12427738
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for the BRCA1 BRCT interaction with the proteins ATRIP and BAAT1.
Liu X; Ladias JA
Biochemistry; 2013 Oct; 52(43):7618-27. PubMed ID: 24073851
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.
Williams RS; Lee MS; Hau DD; Glover JN
Nat Struct Mol Biol; 2004 Jun; 11(6):519-25. PubMed ID: 15133503
[TBL] [Abstract][Full Text] [Related]
20. Classification of BRCA1 missense variants of unknown clinical significance.
Phelan CM; Dapic V; Tice B; Favis R; Kwan E; Barany F; Manoukian S; Radice P; van der Luijt RB; van Nesselrooij BP; Chenevix-Trench G; kConFab ; Caldes T; de la Hoya M; Lindquist S; Tavtigian SV; Goldgar D; Borg A; Narod SA; Monteiro AN
J Med Genet; 2005 Feb; 42(2):138-46. PubMed ID: 15689452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
